Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH
Joost Boeckmans, Karolien Buyl, Alessandra Natale, et al.
Pharmacological Research (2019) Vol. 144, pp. 377-389
Closed Access | Times Cited: 27

Showing 1-25 of 27 citing articles:

Functional Roles of Chemokine Receptor CCR2 and Its Ligands in Liver Disease
Shaoping She, Liying Ren, Pu Chen, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 75
COVID-19 and drug-induced liver injury: a problem of plenty or a petty point?
Joost Boeckmans, Robim M. Rodrigues, Thomas Demuyser, et al.
Archives of Toxicology (2020) Vol. 94, Iss. 4, pp. 1367-1369
Open Access | Times Cited: 126
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism
Joost Boeckmans, Alessandra Natale, Matthias Rombaut, et al.
Cells (2019) Vol. 9, Iss. 1, pp. 37-37
Open Access | Times Cited: 109
Altered Mitochondrial Function in MASLD: Key Features and Promising Therapeutic Approaches
Tatjana Radosavljević, Milica Branković, Janko Samardžić, et al.
Antioxidants (2024) Vol. 13, Iss. 8, pp. 906-906
Open Access | Times Cited: 12
Human Nonalcoholic Steatohepatitis on a Chip
May S. Freag, Bumseok Namgung, Maria E. Reyna Fernandez, et al.
Hepatology Communications (2020) Vol. 5, Iss. 2, pp. 217-233
Open Access | Times Cited: 67
Modeling nonalcoholic fatty liver disease on a liver lobule chip with dual blood supply
Kun Du, Shibo Li, Chengpan Li, et al.
Acta Biomaterialia (2021) Vol. 134, pp. 228-239
Closed Access | Times Cited: 41
Emerging therapeutic options for non-alcoholic fatty liver disease: A systematic review
Jasmine Tidwell, Natalie Balassiano, Anjiya Shaikh, et al.
World Journal of Hepatology (2023) Vol. 15, Iss. 8, pp. 1001-1012
Open Access | Times Cited: 17
State-of-the-art liver disease research using liver-on-a-chip
Sayaka Deguchi, Kazuo Takayama
Inflammation and Regeneration (2022) Vol. 42, Iss. 1
Open Access | Times Cited: 22
A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression
Jaeseo Lee, Dayeon Gil, Hyeyeon Park, et al.
Hepatology (2023) Vol. 80, Iss. 1, pp. 186-201
Closed Access | Times Cited: 14
Concomitant NAFLD Facilitates Liver Metastases and PD-1-Refractory by Recruiting MDSCs via CXCL5/CXCR2 in Colorectal Cancer
Yue Yang, Yunsong Chen, Zhaogang Liu, et al.
Cellular and Molecular Gastroenterology and Hepatology (2024) Vol. 18, Iss. 2, pp. 101351-101351
Open Access | Times Cited: 5
Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease
Mohammad Zarei, David Aguilar-Recarte, Xavier Palomer, et al.
Metabolism (2020) Vol. 114, pp. 154342-154342
Open Access | Times Cited: 35
Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists
Joost Boeckmans, Alessandra Natale, Matthias Rombaut, et al.
Cell Biology and Toxicology (2020) Vol. 37, Iss. 2, pp. 293-311
Closed Access | Times Cited: 33
Lipid accumulation impairs lysosomal acid lipase activity in hepatocytes: Evidence in NAFLD patients and cell cultures
Monica Gomaraschi, Anna Ludovica Fracanzani, Paola Dongiovanni, et al.
Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids (2019) Vol. 1864, Iss. 12, pp. 158523-158523
Closed Access | Times Cited: 31
Metabolic signature of HepaRG cells exposed to ethanol and tumor necrosis factor alpha to study alcoholic steatohepatitis by LC–MS-based untargeted metabolomics
Elias Iturrospe, Rani Robeyns, Katyeny Manuela da Silva, et al.
Archives of Toxicology (2023) Vol. 97, Iss. 5, pp. 1335-1353
Closed Access | Times Cited: 7
Elafibranor: A promising treatment for alcoholic liver disease, metabolic-associated fatty liver disease, and cholestatic liver disease
Hang Zhang, Xuan Dong, Lei Zhu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 40, pp. 4393-4398
Closed Access | Times Cited: 2
Livogrit Prevents Methionine-Cystine Deficiency Induced Nonalcoholic Steatohepatitis by Modulation of Steatosis and Oxidative Stress in Human Hepatocyte-Derived Spheroid and in Primary Rat Hepatocytes
Acharya Balkrishna, Vivek Gohel, Priya Kumari, et al.
Bioengineered (2022) Vol. 13, Iss. 4, pp. 10811-10826
Open Access | Times Cited: 12
Advancements in MAFLD Modeling with Human Cell and Organoid Models
Shixiang Wang, Ji-Song Yan, Yun-Shen Chan
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 19, pp. 11850-11850
Open Access | Times Cited: 12
Transcriptomics Reveals Discordant Lipid Metabolism Effects between In Vitro Models Exposed to Elafibranor and Liver Samples of NAFLD Patients after Bariatric Surgery
Joost Boeckmans, Alexandra Gatzios, Anja Heymans, et al.
Cells (2022) Vol. 11, Iss. 5, pp. 893-893
Open Access | Times Cited: 8
Application of metabolomics in the diagnosis of non-alcoholic fatty liver disease and the treatment of traditional Chinese medicine
Mingmei Shao, Yifei Lü, Hongjiao Xiang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 8
Emerging targets and potential therapeutic agents in non-alcoholic fatty liver disease treatment
Yu Yang, Yu Zhao, Wenzhen Li, et al.
European Journal of Medicinal Chemistry (2020) Vol. 197, pp. 112311-112311
Closed Access | Times Cited: 12
Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models
María Pelechá, Estela Villanueva-Bádenas, Enrique Timor-López, et al.
Antioxidants (2021) Vol. 11, Iss. 1, pp. 86-86
Open Access | Times Cited: 10
Gene Expression Profile Analyses of the Skin Response of Balb/c-Nu Mice Model Injected by Staphylococcus aureus
Jiachan Zhang, Changtao Wang, Quan An, et al.
Clinical Cosmetic and Investigational Dermatology (2022) Vol. Volume 15, pp. 217-235
Open Access | Times Cited: 7
Human skin stem cell-derived hepatic cells as in vitro drug discovery model for insulin-driven de novo lipogenesis
Karolien Buyl, Martine Vrints, Ruani Fernando, et al.
European Journal of Pharmacology (2023) Vol. 957, pp. 175989-175989
Open Access | Times Cited: 3
From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights
Alexandra Gatzios, Matthias Rombaut, Karolien Buyl, et al.
Biomedicines (2022) Vol. 10, Iss. 1, pp. 161-161
Open Access | Times Cited: 5
How Qualification of 3D Disease Models Cuts the Gordian Knot in Preclinical Drug Development
Monika Schäfer‐Korting, Christian Zoschke
Handbook of experimental pharmacology (2020), pp. 29-56
Closed Access | Times Cited: 6
Page 1 - Next Page

Scroll to top